Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration
Status:
Completed
Trial end date:
2019-07-02
Target enrollment:
Participant gender:
Summary
This was a multicenter, open label study that is designed to evaluate the safety of
brolucizumab 6 mg in a prefilled syringe in subjects with neovascular age related macular
degeneration and to support collection of observations of the prefilled syringe use for
intravitreal injection.